CerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox

0

CerTest Biotec uses the BD MAX™ Molecular Diagnostic System Open System Reagent Suite to develop the RT-PCR detection kit

ZARAGOZA, SPAIN and FRANKLIN LAKES, NJ, June 8, 2022 /PRNewswire/ — CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX), a world leader in medical technology, today announced a collaboration to develop a molecular diagnostic test for monkeypox virus.

BD offers a line of open system reagents for the BD MAX™ System that allow laboratories to fully automate and streamline their laboratory-developed tests.

As part of the collaboration, the assay will utilize the BD MAX™ open system reagent suite to validate the CE/IVD molecular test CerTest VIASURE Monkeypox on the BD MAX™ System. The assay will be available to BD MAX™ users and may help improve understanding of the global spread of the disease.

“Enabling laboratories to respond quickly to unexpected challenges is the type of evolving healthcare situation that the BD MAX™ open system reagent suite was designed for,” he said Nikos Pavlidis, Vice President of Molecular Diagnostics at BD. “Through our collaboration with CerTest and their ability to quickly transfer assays to the BD MAX™ System, we will make a monkeypox confirmatory test available to BD MAX™ System users around the world.”

The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR, delivering results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests for the system, covering healthcare associated infections, respiratory tract infections, sexually transmitted infections, gastrointestinal infections and female health diagnostics. BD offers a line of open system reagents for the BD MAX™ System that allow laboratories to fully automate and streamline their laboratory-developed tests, and BD can work with customers to develop complementary assays on the system.

Nelson FernandesManaging Director of CerTest BioTec, added: “The strong capabilities of our teams in rapid molecular assay development as well as our experience working with the BD MAX™ System allows us to accelerate the development of an assay and further expand our collaboration with BD .”

Like all CerTest tests, the Monkeypox PCR Detection Kit for the BD MAX™ System is offered in a lyophilized format. Accordingly, the test is supplied in a tube that snaps into the test specific position on the BD MAX™ ExK™ TNA Extraction Strip supplied by BD.

About CerTest
CerTest Biotec
is a European company founded in 2002 for the development and manufacture of in-vitro diagnostics.

Today, CerTest is a global company consisting of 7 business units offering one of the broadest portfolios in human in vitro diagnostics and pharma. The company is building its future on strong technical knowledge and expertise in human disease detection.

CerTest Latest generation laboratories, state-of-the-art technical equipment and skilled professionals are the keys to providing reliable solutions for the medical diagnostician.

About BD
BD is one of the largest global medical technology companies in the world, advancing the world of health by improving medical discovery, diagnostics and care. The company supports the heroes on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 75,000 employees are passionate and dedicated to improving the safety and efficiency of the care process for clinicians, enabling laboratory scientists to accurately detect disease, and enhancing the capabilities of researchers to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and works with organizations around the world to address some of the toughest global health challenges. By working closely with customers, BD can help improve outcomes, reduce costs, increase efficiencies, improve safety and expand access to healthcare. For more information on BD, see bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BAndCo.

Contacts:

Natalia Bertran

Head of Molecular Diagnostics

(+34) 976 520 354

[email protected]

media:

investors:

Troy Kirkpatrick

Francesca DeMartino

VP, Public Relations

SVP, Head of Investor Relations

858.617.2361

201.847.5743

[email protected]

[email protected]

*The BD and BD MAX trademarks are owned by BD (Becton, Dickinson and Company).

*VIASURE is a registered trademark of CerTest Biotec, SL

BD (Becton, Dickinson and Company) Logo (PRNewsphoto/BD (Becton, Dickinson and Company))

BD (Becton, Dickinson and Company) Logo (PRNewsphoto/BD (Becton, Dickinson and Company))

decision

decision

View the original content to download multimedia:https://www.prnewswire.com/news-releases/certest-biotec-and-bd-announce-collaboration-on-molecular-diagnostic-test-for-monkeypox-301563444.html

SOURCE BD (Becton, Dickinson and Company)

Share.

Comments are closed.